Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. (18th May 2018)

• Record Type: Journal Article
• Authors: Bracarda, Sergio; Galli, Luca; Maruzzo, Marco; Lo Re, Giovanni; Buti, Sebastiano; Favaretto, Adolfo; Di Costanzo, Francesco; Sacco, Cosimo; Merlano, Marco; Mucciarini, Claudia; Zafarana, Elena; Romito, Sante; Maestri, Antonio; Giorgio, Carmelo G; Ionta, Maria T; Turci, Daniele; De Giorgi, Ugo; Procopio, Giuseppe; Cortesi, Enrico; Giannarelli, Diana; Porta, Camillo
• Is Part Of: Future oncology. Volume 14:Number 14(2018)
• Page Start: 1347
• Page End: 1354
• Publication Date: 2018-05-18
• Subjects: EAP -- mRCC -- nivolumab -- prognostic factors; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0570
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: We report the outcomes observed with nivolumab in metastatic renal cell carcinoma patients with poor prognostic features enrolled in the Italian expanded access program.Patients & methods: Nivolumab was available for patients who relapsed after at least one prior systemic treatment in the advanced or metastatic setting.Results: Of 389 patients, 32 (8%) had brain metastasis, 129 (33%) had liver and 193 (50%) had bone metastasis. These subpopulations achieved a disease control rate of 53, 45 and 47%, respectively. Fifty-one patients had G4 tumor, and they showed 23% objective response rate. The safety profile of the subgroups was in line with the expanded access program population. No new safety signals were reported.Conclusion: Patients with poor prognostic features may derive relevant benefits from nivolumab.